Hydroxychloroquine‐induced acute generalized exanthematous pustulosis (AGEP) treated with secukinumab.

This article discusses a case of hydroxychloroquine-induced acute generalized exanthematous pustulosis (AGEP) that was successfully treated with secukinumab, an IL-17 antagonist. AGEP is a rare severe cutaneous adverse reaction characterized by the acute onset of widespread pustules on an erythematous base. Hydroxychloroquine is a commonly used antimalarial drug that can cause AGEP as a skin adverse reaction. The patient in this case experienced worsening symptoms despite treatment with systemic corticosteroids and cyclosporine, but showed significant improvement after receiving secukinumab. This case suggests that IL-17 antagonists could be a promising therapeutic option for refractory cases of AGEP. [Extracted from the article]